Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patients. An early feature of AD is region specific declines in cerebral glucose metabolism. One strategy has been to supplement the brain's normal glucose supply with ketone bodies. The company's data was drawn from two clinical studies which examined the cognitive effects of induced ketosis... (Source: Health News from Medical News Today)